Format

Send to

Choose Destination
See comment in PubMed Commons below
Am J Alzheimers Dis Other Demen. 2010 Mar;25(2):128-33. doi: 10.1177/1533317509356692. Epub 2010 Feb 1.

Off-label medication use in frontotemporal dementia.

Author information

1
Memory and Aging Center, Department of Neurology, University of California-San Francisco, San Francisco, CA 94143, USA.

Abstract

OBJECTIVE:

There are no Food and Drug Administration (FDA)-approved medications indicated for the treatment of frontotemporal dementia (FTD). We sought to determine the most commonly used drugs used to treat behavioral variant FTD (bvFTD) in specialized dementia clinics.

METHODS:

Medication and demographic data from the Alzheimer's Disease Research Centers of California (ARCC) and a multicenter FTD natural history study (NHS) data set were compared in bvFTD and Alzheimer's disease (AD), and effects of demographic variables were assessed using logistic regression.

RESULTS:

Overall, the percentage of patients taking one or more FDA-approved AD or psychiatric medications was similar in bvFTD and AD; however, after controlling for demographic variables, acetylcholinesterase inhibitor (AChI) use was less common in bvFTD, whereas memantine use remained similar in the 2 groups.

CONCLUSIONS:

Despite lack of evidence for efficacy, the use of AChIs and memantine is common in bvFTD. Clinical trials should be pursued to determine the optimal therapeutic interventions for bvFTD.

PMID:
20124256
PMCID:
PMC2862544
DOI:
10.1177/1533317509356692
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon Icon for PubMed Central
    Loading ...
    Support Center